Search

Displaying results 291 - 300 of 392 in total
  1. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.

  2. Drug

    alpha-Tocopherol succinate

    go.drugbank.com/drugs/DB14001
    ApprovedNutraceuticalVet approved

    Alpha-tocopherol is the primary form of vitamin E that is preferentially used by the human body to meet appropriate dietary requirements. In particular, the RRR-alpha-tocopherol (or sometimes called the d-alpha-tocopherol stereoisomer) s...

    Mixtures: Somavit Brand Vitamins and Minerals Complex
  3. Drug

    Zuclopenthixol

    go.drugbank.com/drugs/DB01624
    ApprovedInvestigational

    Major brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes.

  4. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    [L39229] It was approved for use under the brand name Voxzogo (BioMarin Pharmaceutical Inc.) in the EU in August 2021 and the US in November 2021,[L39245,L39241] becoming the first pharmacological intervention

  5. Drug

    Clonazepam

    go.drugbank.com/drugs/DB01068
    ApprovedIllicitInvestigational

    Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year.

  6. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    [A7659,A7660,A254831] Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto.

  7. Drug

    Difelikefalin

    go.drugbank.com/drugs/DB11938
    ApprovedInvestigational

    [A237620] Difelikefalin received FDA approval in August 2021 (under the brand name Korsuva), becoming the first FDA-approved therapy for patients with chronic kidney disease suffering from uremic pruritus

  8. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    [A262021,A262026,A262031] On November 17th, 2023, capivasertib, under the brand name TRUQAP, was approved by the FDA for the treatment of adult patients HR-positive, HER2-negative locally advanced or

  9. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    [A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo.

  10. Drug

    Canakinumab

    go.drugbank.com/drugs/DB06168
    ApprovedInvestigational

    Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are